GSK pulls one Tyverb app, submits another; EMA deems Xenical, Alli worth the liver risks;

@FiercePharma: Risperdal didn't cause one man's diabetes, but J&J didn't do enough to warn his doctor, jury finds--Bloomberg. Story | Follow @FiercePharma

> GlaxoSmithKline ($GSK) pulled its application for broader use of its cancer drug Tyverb in combination with the chemo drug paclitaxel, but filed new requests for its use in combination with Roche's Herceptin. Story

> European regulators determined the benefits of the weight loss drugs Xenical, from Roche ($RHHBY), and Alli, from GlaxoSmithKline, outweigh the small risk of liver-related side effects. Article

> Pfizer ($PFE) and Mylan ($MYL) agreed to settle an EpiPen patent-infringement suit against Sanofi, after the French drugmaker and partner Intelliject agreed to delay the launch of their e-cue injection device until Nov. 15. News

> European regulators issued their final word on medicines made by the troubled contract manufacturer Ben Venue Laboratories. Release

> Two U.S. senators are asking the Justice Department to elucidate its interpretation of the Foreign Corrupt Practices Act, saying businesses are spending too much time second-guessing regulators on the anti-bribery statute. Report

> European regulators recommended broadening use of Amylin Pharmaceuticals' ($AMLN) diabetes drug Byetta as an add-on to insulin therapy. Release

> An implanted, microchip-controlled drug-delivery system worked in its first study, showing promise for improving compliance in patients using injectable drugs. Article

> Roche plans to switch 90,000 employees worldwide to Google Apps for email and calendaring. Story

Biotech News

@FierceBiotech: Humans to test T-cell treatment that subdued canine lymphoma. More | Follow @FierceBiotech

@JohnCFierce: You gotta love the hep C arena right now. $VRTX up, $IDIX down, $GILD wounded. Like 3-D chess: One bad or good move changes the whole game. | Follow @JohnCFierce

@RyanMFierce: As one might expect, more good questions than good answers on the $GILD call this A.M. | Follow @RyanMFierce

@FierceMedDev: Profits at Medtronic down 21%. Article via @the_irish_times | Follow @FierceMedDev

> Gilead disappoints with relapse data in oral Hep C study. News

> MIT scientists tout first human data on drug-delivery chips. Article

> FDA notes concerns about Vivus diet pill safety ahead of panel. Story

And Finally... Pfizer's stop-smoking drug Chantix may make drinking alcohol less pleasurable, researchers found. Article

Suggested Articles

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.